Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779604 | 1.00 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| SCHEMBL29779595 | 1.00 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| SCHEMBL2085504 | 1.00 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| SCHEMBL14862093 | 1.00 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| Hydrochloric Acid SCHEMBL16292918 | 0.98 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| Hydrochloric Acid SCHEMBL4799050 | 0.98 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| SCHEMBL20217280 | 0.92 | KCNA5 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| SCHEMBL12789439 | 0.92 | KCNA5 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| SCHEMBL14862495 | 0.92 | KCNA5 (0.44) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 | |
| Hydrochloric Acid SCHEMBL15400032 | 0.91 | KCNA5 (0.43) | SLC6A4SLC6A2SLC6A3KCNA5KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-8980934-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2015-03-17 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140005167-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2014-01-02 | — | — | US | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005167-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | SLC6A4 2987/4885SLC6A2 2706/4885SLC6A3 3033/4885 |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | SLC6A4 3443/4885SLC6A2 4715/4885SLC6A3 4293/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | SLC6A4 2987/4885SLC6A2 2706/4885SLC6A3 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.